Phase 2
Moderna unleashed a torrent of updates yesterday.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo.
Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.
Another attempt at developing a treatment for Alzheimer’s has hit a wall.
An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.
Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
PRESS RELEASES